|
|
[Report]
Pipeline Insight: Dyslipidemia - Pipeline agents unlikely to rejuvenate the market
Published: 2007/04
|
|
 |
|
|
|
|
Table of Contents
- About the cardiovascular pharmaceutical analysis team
- CHAPTER 1 EXECUTIVE SUMMARY
- Scope of the analysis
- Datamonitor insight into the dyslipidemia market
- Single-pill combinations have their appeal, but not for every market
- Increased efficacy in HDL-C raising is the most important unmet need,
but the fiasco of torcetrapib will impede speedy launch of efficacious
HDL-raising agents
- Innovation is scarce among the pipeline agents
- The crowded antidyslipidemic market undergoing high genericization
will make it challenging for the developmental compounds to secure a share
of the market
- Datamonitor Pipeline Assessment Summary
- CHAPTER 2 PIPELINE OVERVIEW AND DYNAMICS
- Pipeline overview
- The antidyslipidemic pipeline is mechanistically diversified
- The antidyslipidemic pipeline is rich in Phase I and Phase II candidates
- Numerous companies have their stake in the R&D landscape
- Abbott holds most advanced developmental agents, but no innovation value
- Merck - unclear whether there is innovation in the pipeline
- GSK and Japan Tobacco hold more promise to satisfy the unmet needs
- Key R&D company strategies
- CHAPTER 3 DYSLIPIDEMIA - MARKET POTENTIAL
- Definition of dyslipidemia
- Segmentation of dyslipidemia
- Markers for dyslipidemia
- Main types of dyslipidemia
- Hypercholesterolemia
- Familial hypercholesterolemia
- Hypertriglyceridemia
- Familial hypertriglyceridemia
- Mixed dyslipidemia
- Epidemiology of dyslipidemia
- Epidemiology methodology
- US
- Japan
- France
- Germany
- Italy
- Spain
- UK
- Unmet needs in dyslipidemia
- Major obstacles between the drugs and the market
- Increased efficacy in raising HDL-cholesterol
- Drugs with novel mechanisms of actions
- Ability to prevent or even reverse the progression of atherosclerosis
- Increased efficacy in lowering LDL-C
- Combination therapies to treat patients with complicated lipid profiles
- Long-term data to support prevention of acute CVD events
- Further statin safety data
- CHAPTER 4 R&D APPROACH
- Classification of pipeline products
- Statins and statin combinations
- Statins dominate the antidyslipidemic market
- Mechanism of action
- Fibrates - PPAR-alpha agonists
- Cholesteryl ester transfer protein (CETP) inhibitors: targeting HDL-C
- Lipoprotein lipase activator
- Microsomal triglyceride transfer (MTP) inhibitors
- Squalene synthase inhibitor
- Apolipoprotein B100 antagonist
- Dual PPAR agonists
- PPAR- delta agonists
- Transcription factor inhibitor
- Cholesterol transport/absorption Inhibitors
- Clinical trial design in dyslipidemia
- Short-term endpoints: controlling cholesterol levels
- Long-term endpoints: reduction in morbidity and mortality
- CHAPTER 5 STATINS AND STATIN COMBINATIONS - LATE-STAGE DRUG ANALYSIS &
FORECASTS
- Overview for statins and statin combinations
- Pipeline summary
- Comparative forecasts
- Definition of current comparator therapy
- Pfizer' s Lipitor remains the current comparator therapy
- Pitavastatin
- Drug overview
- Clinical trial data
- Patient potential
- Marketing factors
- Satisfaction of unmet needs
- Forecasts to 2016
- Datamonitor drug assessment summary
- KS-01-019 (Simcor; Simvastatin + niacin ER)
- Drug overview
- Clinical trial data
- Patient potential
- Marketing factors
- Satisfaction of unmet needs
- Forecasts to 2016
- Datamonitor drug assessment summary
- Zolip (simvastatin + fenofibrate)
- Drug overview
- Clinical trial data
- Patient potential
- Marketing factors
- Satisfaction of unmet needs
- Forecasts to 2016
- Datamonitor drug assessment summary
- Other statins/statin combinations
- Rosuvastatin + ABT-335
- MK-0524B
- CHAPTER 6 OTHER THERAPIES - LATE-STAGE DRUG ANALYSIS AND FORECASTS
- Overview for other therapies
- Pipeline summary
- Comparative forecasts
- Definition of current comparator therapy
- Niacin remains the HDL raising agent with highest efficacy
- Ezetimibe remains the biggest revenue generating adjunct therapy
- Lapaquistat
- Drug overview
- Clinical trial data
- Patient potential
- Marketing factors
- Satisfaction of unmet needs
- Forecasts to 2016
- Datamonitor drug assessment summary
- JTT-705 (R1658)
- Drug overview
- Clinical trial data
- 34% increase in HDL in Phase II clinical trials
- Ongoing clinical trials
- Patient potential
- Marketing factors
- Satisfaction of unmet needs
- Forecasts to 2016
- Datamonitor drug assessment summary
- FM-VP4 (phytosterol analogue)
- Drug overview
- Clinical trial data
- Phase I trials show excellent safety profile
- Phase II trials bring forward disappointing efficacy
- Patient potential
- Marketing factors
- FM VP4 will require a marketing partner
- Satisfaction of unmet needs
- Forecasts to 2016
- Datamonitor drug assessment summary
- ISIS-301012, injectable
- Drug overview
- Clinical trial data
- Phase II results
- Phase I results
- Patient potential
- Marketing factors
- Satisfaction of unmet needs
- Forecasts to 2016
- Datamonitor drug assessment summary
- Other agents
- MK-0524A
- Clinical Trials
- Trial Results
- ABT-335
- MD-0727
- CRD-5
- KB-2115
- CETi-1 (vaccine)
- Implitapide (BAY-13-9952; AEGR-427)
- MK-0859
- AEGR-733 (BMS-201038)
- QC-BT16
- LY-674 (LY-518674)
- KRP-101
- 3,5-diiodothyropropionic acid (DITPA)
- Ibrolipim (NO-1886)
- AVE-0847
- LBM-642
- GW-501516
- GW-590735
- GFT-14
- Fenofibrate and pravastatin
- BIBLIOGRAPHY
- Bibliography
- Epidemiology sources
- US
- Japan
- France
- Germany
- Italy
- Spain
- UK
- Clinical trial data
- APPENDIX A
- Methodology
- Product forecasts
- Definition of a standard unit (only use if ForeSight model used to
forecast)
- APPENDIX B
- About the Disease analysis team
- List of Tables
- Table 1: R&D pipeline in Dyslipidemia, 2007
- Table 2: The pipeline for antidyslipidemic agents by mechanism of
action, 2007
- Table 3: Pipeline of antidyslipidemic agents by company, 2007
- Table 4: Key changes to lipid levels between the NCEP II and NCEP III
- Table 5: Prevalence estimates of dyslipidemia (000s), 2007-16
- Table 6: Currently available statins, 2007
- Table 7: Key products in the late-stage R&D pipeline for statins
and statin combinations, 2007
- Table 8: Lipitor: key facts, 2007
- Table 9: Ability of pitavastatin to satisfy the unmet needs
- Table 10: Impacting factors on the revenues of pitavastatin, 2007-2016
- Table 11: Ability of Simcor to satisfy the unmet needs
- Table 12: Impacting factors on the revenues of Simcor, 2007-2016
- Table 13: Ability of Zolip to satisfy the unmet needs
- Table 14: Impacting factors on the revenues of Zolip, 2007-2016
- Table 15: Key products in late-stage R&D pipeline for other
therapies, 2007
- Table 16: Niaspan: key facts, 2007
- Table 17: Zetia: key facts, 2007
- Table 18: Ability of Lapaquistat to satisfy the unmet needs
- Table 19: Impacting factors on the revenues of Lapaquistat, 2007-2016
- Table 20: Ability of JTT-705 to satisfy the unmet needs
- Table 21: Impacting factors on the revenues of JTT-705, 2007-2016
- Table 22: Ability of FM-VP4 to satisfy the unmet needs
- Table 23: Impacting factors on the revenues of FM-VP4, 2007-2016
- Table 24: Ability of ISIS-301012 (injectable) to satisfy the unmet
needs
- Table 25: Impacting factors on the revenues of ISIS-301012
(injectable), 2007-2016
- Table 26: Datamonitor drug assessment parameters
- List of Figures
- Figure 1: drug assessment summary of statins and statin combinations
in development for dyslipidemia, 2007
- Figure 2: drug assessment summary of other therapies in development
for dyslipidemia, 2007
- Figure 3: Pipeline of antidyslipidemic compounds, 2007
- Figure 4: The pipeline for antidyslipidemic agents by mechanism of
action, 2007
- Figure 5: Pipeline maturity: percentage of R&D products in each
Phase of development, 2007
- Figure 6: Unmet needs in the dyslipidemia market, 2007
- Figure 7: drug assessment summary of statins and statin combinations
in development for dyslipidemia, 2007
- Figure 8: Sales forecasts for statins and statin combinations, seven
major markets, 2007-2016
- Figure 9: Sales forecast for Pitavastatin in dyslipidemia to 2016,
seven major markets
- Figure 10 competitive positioning analysis of Pitavastatin, 2007
- Figure 11: Clinical and commercial attractiveness of pitavastatin
broken down by main parameters
- Figure 12: Sales forecast for Simcor in dyslipidemia to 2016, seven
major markets
- Figure 13: competitive positioning analysis of KS-01-19 (Simcor), 2007
- Figure 14: Clinical and commercial attractiveness of Simcor broken
down by main parameters
- Figure 15: Sales forecast for Zolip in dyslipidemia to 2016, seven
major markets
- Figure 16:competitive positioning analysis of Zolip, 2007
- Figure 17: Clinical and commercial attractiveness of Zolip broken down
by main parameters
- Figure 18: Datamonitor drug assessment summary of other therapies in
development for dyslipidemia, 2007
- Figure 19: Sales forecasts for other therapies, seven major markets,
2007-2016
- Figure 20: Sales forecast for Lapaquistat in dyslipidemia to 2016,
seven major markets
- Figure 21: competitive positioning analysis of Lapaquistat, 2007
- Figure 22: Clinical and commercial attractiveness of Lapaquistat
broken down by main parameters
- Figure 23: Sales forecast for JTT-705 in dyslipidemia to 2016, seven
major markets
- Figure 24: competitive positioning analysis of JTT-705, 2007
- Figure 25: Clinical and commercial attractiveness of JTT-705 broken
down by main parameters
- Figure 26: Sales forecast for FM-VP4 in dyslipidemia to 2016, seven
major markets
- Figure 27: competitive positioning analysis of FM-VP4, 2007
- Figure 28: Clinical and commercial attractiveness of FM-VP4 broken
down by main parameters
- Figure 29: Sales forecast for ISIS-301012 (injectable) in dyslipidemia
to 2016, seven major markets
- Figure 30: competitive positioning analysis of ISIS-301012
(injectable), 2007
- Figure 31: Clinical and commercial attractiveness of ISIS-301012
(injectable) broken down by main parameters
- Figure 32: drug assessment summary of pipeline molecular targeted
therapies in development for hematological malignancies, 2007
|
|
|
|
|
|
|
|
[Report]
Pipeline Insight: Dyslipidemia - Pipeline agents unlikely to rejuvenate the market
Published: 2007/04
|
Published by : Datamonitor  |
|
|
Price:
|
Product Code : DC51201 |
|
|
Please inform me when related publications are released
|
|
|
View Cart
